Inhibrx Biosciences Inc (INBX)

12:56 PM

How the (INBX) price action is used to our Advantage - Stock Traders Daily

12:56 PM

Feb 17, 2025

A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News

Feb 17, 2025

Feb 11, 2025

When the Price of (INBX) Talks, People Listen - Stock Traders Daily

Feb 11, 2025

Feb 05, 2025

BlackRock, Inc. Increases Stake in Inhibrx Biosciences Inc. - GuruFocus.com

Feb 05, 2025

Jan 31, 2025

(INBX) Trading Signals - Stock Traders Daily

Jan 31, 2025

Jan 23, 2025

Inhibrx reports promising ozekibart trial results - MSN

Jan 23, 2025

Jan 23, 2025

Inhibrx's SWOT analysis: oncology biotech stock faces pivotal year ahead - MSN

Jan 23, 2025

Jan 21, 2025

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 - GuruFocus.com

Jan 21, 2025

Jan 21, 2025

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer – Company Announcement - Financial Times

Jan 21, 2025

Jan 21, 2025

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer - PR Newswire

Jan 21, 2025

Jan 20, 2025

How to Take Advantage of moves in (INBX) - Stock Traders Daily

Jan 20, 2025

Jan 14, 2025

Inhibrx Biosciences enters $150M loan facility - MSN

Jan 14, 2025

Jan 13, 2025

Inhibrx Biosciences, Inc. Announces Loan Agreement with Oxford Finance LLC - Marketscreener.com

Jan 13, 2025

Jan 13, 2025

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - StreetInsider.com

Jan 13, 2025

Jan 10, 2025

(INBX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Jan 10, 2025

Dec 30, 2024

How To Trade (INBX) - Stock Traders Daily

Dec 30, 2024

Dec 17, 2024

Inhibrx's SWOT analysis: biotech stock faces pivotal year amid clinical trials - Investing.com India

Dec 17, 2024

Dec 09, 2024

(INBX) Trading Report - Stock Traders Daily

Dec 09, 2024

Dec 05, 2024

Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Nigeria

Dec 05, 2024

Dec 05, 2024

Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com

Dec 05, 2024

Dec 02, 2024

2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - News & Insights

Dec 02, 2024

Nov 22, 2024

Inhibrx Biosciences director Jon Faiz Kayyem buys $1.52m in stock - Investing.com Nigeria

Nov 22, 2024

Nov 18, 2024

Trend Tracker for (INBX) - Stock Traders Daily

Nov 18, 2024

Nov 17, 2024

The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares - Yahoo Finance

Nov 17, 2024

Nov 17, 2024

institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St

Nov 17, 2024

Nov 15, 2024

Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Inhibrx Biosciences Inc (INBX) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Nov 14, 2024

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire

Nov 14, 2024

Nov 12, 2024

Inhibrx Biosciences Inc. (INBX) Quarterly 10-Q Report - Quartzy

Nov 12, 2024

Nov 09, 2024

Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com

Nov 09, 2024

Nov 07, 2024

Inhibrx Biosciences’ Trade Secret Case - Global Legal Chronicle

Nov 07, 2024

Nov 05, 2024

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha

Nov 05, 2024

Nov 04, 2024

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - Financial Times

Nov 04, 2024

Oct 25, 2024

James Sabry on industry-shaping changes in innovation and deal-making - BioCentury

Oct 25, 2024

Oct 06, 2024

Long Term Trading Analysis for (INBX) - Stock Traders Daily

Oct 06, 2024

Oct 01, 2024

Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year - Investing.com Australia

Oct 01, 2024

Sep 30, 2024

Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year By Investing.com - Investing.com South Africa

Sep 30, 2024

Sep 19, 2024

why ImmunityBio Inc [IBRX] is a Good Choice for Investors After New Price Target of $6.38 - The DBT News

Sep 19, 2024

Sep 19, 2024

INVX underperforms with a -2.86 decrease in share price - US Post News

Sep 19, 2024

Sep 19, 2024

You might want to take a look at Imunon Inc (IMNN) now - SETE News

Sep 19, 2024

Sep 19, 2024

Immuneering Corp [IMRX] Shares Fall Approximately -71.25% Over the Year - Knox Daily

Sep 19, 2024

Sep 19, 2024

ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Private Advisor Group LLC - Defense World

Sep 19, 2024

Sep 19, 2024

Incyte (NASDAQ:INCY) Given “Hold” Rating at Truist Financial - Defense World

Sep 19, 2024

Sep 19, 2024

Inhibrx, Inc. (NASDAQ:INBX) Short Interest Down 6.9% in August - Defense World

Sep 19, 2024

Sep 18, 2024

InnovAge (NASDAQ:INNV) Trading Up 4.2% - Defense World

Sep 18, 2024

Sep 18, 2024

William Hoffman Sells 40,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) Stock - Defense World

Sep 18, 2024

Sep 18, 2024

INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest - Defense World

Sep 18, 2024

Sep 18, 2024

INmune Bio stock remains a Buy with positive data correlation in Alzheimer’s study, says Scotiabank - Investing.com

Sep 18, 2024

Sep 18, 2024

A review of IMNN’s current quarter earnings predictions - US Post News

Sep 18, 2024